8-K: BiomX to Acquire Adaptive Phage Therapeutics, Bolstering Pipeline with $50 Million Financing

BiomX Inc. is set to acquire Adaptive Phage Therapeutics, enhancing its phage therapy pipeline and securing $50 million in private financing.

Summary

• BiomX Inc. has agreed to acquire Adaptive Phage Therapeutics (APT), a move that will significantly expand its phage therapy pipeline.
• The acquisition includes two Phase 2 programs expected to yield results in 2025, focusing on cystic fibrosis and diabetic foot osteomyelitis.
• APT brings extensive clinical experience with approximately 80 compassionate use cases and multiple clinical studies.
• The combined entity will have a strong investor base, including Deerfield, AMR Fund, Orbimed, and the CF Foundation.
• APT has secured over $40 million in non-dilutive government funding from agencies like the Defense Health Agency and NIH.
• The acquisition will also provide access to a large phage collection, including 185 phages cleared for investigational use and hundreds more targeting various bacteria.
• The combined company will have advanced CMC capabilities with GMP-certified facilities and a capacity of up to 40L.
• BiomX has also secured a $50 million private placement financing led by Deerfield and AMR Fund, with participation from Orbimed, CF Foundation and Nantahala Capital.
• The transaction is expected to close on the first business day following the satisfaction or waiver of certain customary closing conditions, but no earlier than March 12, 2024.

Sentiment

Score: 8

Explanation: The document is highly positive due to the strategic acquisition, strong financial backing, and promising clinical pipeline. The sentiment is slightly tempered by the inherent risks associated with clinical development and regulatory approvals.

Positives

• The acquisition will significantly expand BiomX's phage therapy pipeline.
• The combined company will have a strong investor base and significant non-dilutive funding.
• The acquisition will provide access to a large phage collection and advanced CMC capabilities.
• The private placement financing will provide additional capital for the combined company.
• The merger is expected to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Negatives

• The merger is subject to customary closing conditions, which may delay or prevent the transaction from closing.
• The company will need to obtain stockholder approval for the conversion of the preferred stock and the new incentive plan.
• The company will need to file a registration statement for the resale of the shares issued in the merger and private placement.

Risks

• The merger may not close if the conditions are not met or waived.
• The company may not be able to obtain stockholder approval for the conversion of the preferred stock and the new incentive plan.
• The company may not be able to file a registration statement for the resale of the shares issued in the merger and private placement.
• The company may not be able to successfully develop and commercialize the phage therapy products acquired in the merger.
• The company may not be able to maintain its listing on the NYSE American.

Future Outlook

The company expects to advance its clinical programs, with Phase 2 readouts expected in 2025. The company also plans to seek regulatory feedback and secure additional funding for its programs.

Industry Context

The acquisition reflects a growing interest in phage therapy as a potential solution to antibiotic resistance, a significant challenge in treating bacterial infections. The combined company will be a leader in the phage therapy space.

Comparison to Industry Standards

• The acquisition of APT positions BiomX as a leader in the phage therapy space, comparable to companies like Armata Pharmaceuticals and Felix Biotechnology, which are also developing phage-based treatments.
• The clinical pipeline of the combined company, with two Phase 2 programs, is competitive with other companies in the field.
• The $50 million private placement financing is a significant investment in the company and its technology, comparable to recent funding rounds for other biotech companies in the space.
• The extensive clinical experience of APT, with ~80 compassionate use cases, is a significant advantage compared to other companies in the field.
• The large phage collection and advanced CMC capabilities of the combined company are also competitive advantages.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the expanded pipeline and potential for future growth.
• Employees will have opportunities to work on innovative phage therapy programs.
• Patients will have access to new treatment options for serious infections.
• Creditors will be repaid in accordance with the terms of their agreements.

Next Steps

• The company will seek stockholder approval for the conversion of the preferred stock and the new incentive plan.
• The company will file a registration statement for the resale of the shares issued in the merger and private placement.
• The company will advance its clinical programs, with Phase 2 readouts expected in 2025.
• The company will seek regulatory feedback and secure additional funding for its programs.

Key Dates

Keywords

phage therapy, acquisition, biomx, adaptive phage therapeutics, cystic fibrosis, diabetic foot osteomyelitis, private placement, clinical trials, bacteriophage, antibiotic resistance